Crucell is anticipating a long-term growth from cell-based flu through collaborations with its partners. As part of its influenza strategy, the company recently purchased 20% of Taiwan’s AdImmume with the view of maximizing future growth of Inflexal^® V. Crucell, which is anticipating worldwide growth of Inflexal^® V as premium thiomersal free flu shot, was a recent recipient of a €1.7 European Commission-funded grant toward the development of a pandemic influenza vaccine.